Concord Drugs

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE858L01010
NSEID:
BSEID: 538965
View on BSE

INR

78.44

2.61 (3.44%)

BSENSE

Sep 25, 12:03 PM

BSE+NSE Vol: 3.15 k

{
  "main_header": {
    "sid": 605306,
    "name": "Concord Drugs",
    "stock_name": "Concord Drugs",
    "full_name": "Concord Drugs Ltd",
    "name_url": "stocks-analysis/concord-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "78.44",
    "chg": 2.61,
    "chgp": "3.44%",
    "dir": 1,
    "prev_price": "75.83",
    "mcapval": "100.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 538965,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE858L01010",
    "curr_date": "Sep 25, 12:03 PM",
    "curr_time": "12:07 PM",
    "last_traded_at": "Sep 25, 12:03 PM IST",
    "bse_nse_vol": "3.15 k",
    "exc_status": "Active",
    "traded_date": "Sep 25, 2026",
    "traded_date_str": "2026 09 25",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/concord-drugs-605306-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Concord Drugs Ltd Upgraded to Hold by MarketsMOJO on Technical and Financial Improvements",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-upgraded-to-hold-by-marketsmojo-on-technical-and-financial-improvements-4203033",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/ConcordDrugsLtd_mojoScore_4203033.png",
        "date": "2026-09-24 08:08:38",
        "description": "Concord Drugs Ltd has seen its investment rating upgraded from Sell to Hold, reflecting notable improvements in technical indicators and robust quarterly financial performance. The pharmaceutical company’s recent results, combined with a stabilising technical trend and attractive valuation metrics, have prompted analysts to revise their outlook, signalling cautious optimism amid mixed long-term fundamentals."
      },
      {
        "title": "Concord Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-downgraded-to-sell-amid-mixed-financial-and-technical-signals-4199214",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/ConcordDrugsLtd_mojoScore_4199214.png",
        "date": "2026-09-21 08:06:47",
        "description": "Concord Drugs Ltd has seen its investment rating downgraded from Hold to Sell, reflecting a complex interplay of technical weakness, valuation concerns, and subdued long-term financial fundamentals despite recent strong quarterly earnings. The downgrade, effective from 18 September 2026, highlights deteriorating technical trends and persistent challenges in the company’s financial health, prompting a cautious stance for investors."
      },
      {
        "title": "Concord Drugs Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-hold-4196138",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/ConcordDrugsLtd_mojoScore_4196138.png",
        "date": "2026-09-17 10:11:20",
        "description": "Concord Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 31 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Concord Drugs Ltd Edges Down 0.38% Despite Technical Upgrade and Valuation Shift",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-drugs-ltd-edges-down-038-despite-technical-upgrade-and-valuation-shift-4183806",
        "imagepath": "",
        "date": "2026-09-05 16:11:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>31 Aug:</strong> Valuation shifts to fair amid strong market performance</p>\n                    <p><strong>1 Sep:</strong> Upgraded to Hold on improved technicals and attractive valuation</p>\n                    <p><strong>4 Sep:</strong> Week closes at Rs.80.82 (-0.38%) outperforming Sensex</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.81.13</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.80.82</div><div class=\"stat-change negative\">-0.38%</div></div>\n                    <div c..."
      },
      {
        "title": "Concord Drugs Ltd Upgraded to Hold on Improved Technicals and Attractive Valuation",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-upgraded-to-hold-on-improved-technicals-and-attractive-valuation-4177050",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/ConcordDrugsLtd_mojoScore_4177050.png",
        "date": "2026-09-01 08:13:39",
        "description": "Concord Drugs Ltd has seen its investment rating upgraded from Sell to Hold as of 31 August 2026, reflecting a notable improvement in its technical outlook and valuation metrics. Despite a slight dip in the share price on 1 September 2026, the micro-cap pharmaceutical company’s recent financial performance and market returns have prompted a reassessment of its prospects."
      },
      {
        "title": "Concord Drugs Ltd Valuation Shifts to Fair Amidst Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-drugs-ltd-valuation-shifts-to-fair-amidst-strong-market-performance-4175265",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/ConcordDrugsLtd_valuationdot_4175265.png",
        "date": "2026-08-31 08:00:39",
        "description": "Concord Drugs Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating as of late July 2026. This change reflects evolving market perceptions amid a competitive pharmaceuticals and biotechnology sector, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now aligning more closely with sector peers. Investors are advised to consider these valuation adjustments alongside Concord Drugs’ recent performance and sector trends to gauge its price attractiveness."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-4166721",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/ConcordDrugsLtd_mojoScore_4166721.png",
        "date": "2026-08-24 10:10:49",
        "description": "Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 21 July 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 24 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Concord Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-drugs-ltd-is-rated-sell-4151632",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/ConcordDrugsLtd_mojoScore_4151632.png",
        "date": "2026-08-13 10:11:00",
        "description": "Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "When is the next results date for Concord Drugs Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-concord-drugs-ltd-4136320",
        "imagepath": "",
        "date": "2026-08-04 23:18:22",
        "description": "The next results date for Concord Drugs Ltd is scheduled for 10 August 2026...."
      }
    ],
    "total": 306,
    "sid": "605306",
    "stock_news_url": "https://www.marketsmojo.com/news/concord-drugs-605306"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "09-Sep-2026",
      "details": "Copies of News paper publications of the Notice of the 31st AGM to be held on 30.09.2026",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Annual General Meeting To Be Held On 30.09.2026",
      "datetime": "07-Sep-2026",
      "details": "Company has approved the notice and proposed to hold 31st AGM on 30.09.2026",
      "source": "BSE"
    },
    {
      "caption": "31St Annual General Meeting",
      "datetime": "07-Sep-2026",
      "details": "AGM to be held on 30.09.2026 at 09:00 AM",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Concord Drugs Ltd Upgraded to Hold by MarketsMOJO on Technical and Financial Improvements

2026-09-24 08:08:38

Concord Drugs Ltd has seen its investment rating upgraded from Sell to Hold, reflecting notable improvements in technical indicators and robust quarterly financial performance. The pharmaceutical company’s recent results, combined with a stabilising technical trend and attractive valuation metrics, have prompted analysts to revise their outlook, signalling cautious optimism amid mixed long-term fundamentals.

Read full news article

Concord Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals

2026-09-21 08:06:47

Concord Drugs Ltd has seen its investment rating downgraded from Hold to Sell, reflecting a complex interplay of technical weakness, valuation concerns, and subdued long-term financial fundamentals despite recent strong quarterly earnings. The downgrade, effective from 18 September 2026, highlights deteriorating technical trends and persistent challenges in the company’s financial health, prompting a cautious stance for investors.

Read full news article

Concord Drugs Ltd is Rated Hold

2026-09-17 10:11:20

Concord Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 31 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Concord Drugs Ltd Edges Down 0.38% Despite Technical Upgrade and Valuation Shift

2026-09-05 16:11:04

Key Events This Week

31 Aug: Valuation shifts to fair amid strong market performance

1 Sep: Upgraded to Hold on improved technicals and attractive valuation

4 Sep: Week closes at Rs.80.82 (-0.38%) outperforming Sensex

Read full news article

Concord Drugs Ltd Upgraded to Hold on Improved Technicals and Attractive Valuation

2026-09-01 08:13:39

Concord Drugs Ltd has seen its investment rating upgraded from Sell to Hold as of 31 August 2026, reflecting a notable improvement in its technical outlook and valuation metrics. Despite a slight dip in the share price on 1 September 2026, the micro-cap pharmaceutical company’s recent financial performance and market returns have prompted a reassessment of its prospects.

Read full news article

Concord Drugs Ltd Valuation Shifts to Fair Amidst Strong Market Performance

2026-08-31 08:00:39

Concord Drugs Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating as of late July 2026. This change reflects evolving market perceptions amid a competitive pharmaceuticals and biotechnology sector, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now aligning more closely with sector peers. Investors are advised to consider these valuation adjustments alongside Concord Drugs’ recent performance and sector trends to gauge its price attractiveness.

Read full news article

Concord Drugs Ltd is Rated Sell

2026-08-24 10:10:49

Concord Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 21 July 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 24 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Concord Drugs Ltd is Rated Sell

2026-08-13 10:11:00

Concord Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.